Loss of CD30 expression in anaplastic large cell lymphoma following brentuximab therapy

Journal of Drugs in Dermatology

Volumn 15, Issue 7, 2016, Pages 894-895

  Nielson, Colton ^b   Fischer, Ryan ^a   Fraga, Garth ^a   Aires, Daniel ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

AGED; ANAPLASTIC LARGE CELL LYMPHOMA; ARTICLE; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; GANGRENE; HUMAN; IMMUNOPHENOTYPING; MALE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PUNCH BIOPSY; T LYMPHOCYTE; BIOSYNTHESIS; CHEMICALLY INDUCED; GENE EXPRESSION REGULATION; LYMPHOMA, LARGE-CELL, ANAPLASTIC; METABOLISM; TUMOR RECURRENCE;

AGED; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 85006981837     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Querfield, Christiane. Primary Cutaneous and Systemic Anaplastic large cell lymphoma. Oncology. 2010;24:574-87.
2. Jaffe, Elaine S. Anaplastic large cell lymphoma: The shifting sands of diagnostic hematopathology. Mod Patho. 2001;14:219-28.
3. Mehra, Tarun, Kristian Ikenberg, and Rudolf Maria Moos. Brentuximab as a treatment for CD30 mycosis fungoides and sézary syndrome. JAMA Dermatol.
4. Hsu, F. Y.-Y. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated junB level in a cell type-specific manner. Cancer Res. 2006;66:9002-008.
5. Corey, Kristen, Deborah Cook, Jessica Bekker. A case of refractory sézary syndrome with large-cell transformation responsive to brentuximab vedotin." JAMA Dermatol. 2014;150:210.
6. Zinzani, P.l., S. Sasse, J. Radford, O. Shonukan, and V. Bonthapally. Experience of brentuximab vedotin in relapsed/refractory hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the named patient program: review of the literature. Crit Rev Oncol Hematol. 2015;95:359-69.